Background
Asthma is a chronic inflammatory disorder of the airways characterized by an obstruction of airflow, which may be completely or partially reversed with or without specific therapy. Airway inflammation is the result of interactions between various cells, cellular elements, and cytokines. In susceptible individuals, airway inflammation may cause recurrent or persistent bronchospasm, which causes symptoms that include wheezing, breathlessness, chest tightness, and cough, particularly at night (early morning hours) or after exercise.
Airway inflammation is associated with airway hyperreactivity or bronchial hyperresponsiveness (BHR), which is defined as the inherent tendency of the airways to narrow in response to various stimuli (eg, environmental allergens and irritants).[1]
Asthma affects an estimated 300 million individuals worldwide (see Epidemiology). The prevalence of asthma is increasing, especially in children. Annually, the World Health Organization (WHO) has estimated that 15 million disability-adjusted life-years are lost and 250,000 asthma deaths are reported worldwide.[2] Approximately 500,000 annual hospitalizations (34.6% in individuals aged 18 y or younger) are due to asthma. In the United States, asthma prevalence, having increased from 1980 to 1996, showed a plateau at 9.1% of children (6.7 million) in 2007.[3]
The cost of illness related to asthma is around $6.2 billion. Each year, an estimated 1.81 million people (47.8% in individuals aged 18 y or younger) require treatment in the emergency department. Among children and adolescents aged 5-17 years, asthma accounts for a loss of 10 million school days and costs caretakers $726.1 million because of work absence.[4]
Guidelines from the National Asthma Education and Prevention Program provide recommendations on the diagnosis and treatment of pediatric asthma (see Clinical Presentation, Workup, and Treatment and Management).
For more information, see the Medscape Reference topic Asthma.
Pathophysiology
Interactions between environmental and genetic factors result in airway inflammation, which limits airflow and leads to functional and structural changes in the airways in the form of bronchospasm, mucosal edema, and mucus plugs.
Airway obstruction causes increased resistance to airflow and decreased expiratory flow rates. These changes lead to a decreased ability to expel air and may result in hyperinflation. The resulting overdistention helps maintain airway patency, thereby improving expiratory flow; however, it also alters pulmonary mechanics and increases the work of breathing.
Hyperinflation compensates for the airflow obstruction, but this compensation is limited when the tidal volume approaches the volume of the pulmonary dead space; the result is alveolar hypoventilation. Uneven changes in airflow resistance, the resulting uneven distribution of air, and alterations in circulation from increased intra-alveolar pressure due to hyperinflation all lead to ventilation-perfusion mismatch.
Vasoconstriction due to alveolar hypoxia also contributes to this mismatch. Vasoconstriction is also considered an adaptive response to ventilation/perfusion mismatch.
In the early stages, when ventilation-perfusion mismatch results in hypoxia, hypercarbia is prevented by the ready diffusion of carbon dioxide across alveolar capillary membranes. Thus, patients with asthma who are in the early stages of an acute episode have hypoxemia in the absence of carbon dioxide retention. Hyperventilation triggered by the hypoxic drive also causes a decrease in PaCO2. An increase in alveolar ventilation in the early stages of an acute exacerbation prevents hypercarbia.
With worsening obstruction and increasing ventilation-perfusion mismatch, carbon dioxide retention occurs. In the early stages of an acute episode, respiratory alkalosis results from hyperventilation. Later, the increased work of breathing, increased oxygen consumption, and increased cardiac output result in metabolic acidosis. Respiratory failure leads to respiratory acidosis.
Role of inflammation
Chronic inflammation of the airways is associated with increased BHR, which leads to bronchospasm and typical symptoms of wheezing, shortness of breath, and coughing after exposure to allergens, environmental irritants, viruses, cold air, or exercise. In some patients with chronic asthma, airflow limitation may be only partially reversible because of airway remodeling (hypertrophy and hyperplasia of smooth muscle, angiogenesis, and subepithelial fibrosis) that occurs with chronic untreated disease.
New insights in the pathogenesis of asthma suggest that lymphocytes play a role. Airway inflammation in asthma may represent a loss of normal balance between two "opposing" populations of T helper (Th) lymphocytes. Two types of Th lymphocytes have been characterized: Th1 and Th2. Th1 cells produce interleukin (IL)-2 and interferon-α (IFN-α), which are critical in cellular defense mechanisms in response to infection. Th2, in contrast, generates a family of cytokines (interleukin-4 [IL-4], IL-5, IL-6, IL-9, and IL-13) that can mediate allergic inflammation.
The hygiene hypothesis
The current "hygiene hypothesis" of asthma illustrates how this cytokine imbalance may explain some of the dramatic increases in asthma prevalence in Westernized countries.[5] This hypothesis is based on the concept that the immune system of the newborn is skewed toward Th2 cytokine generation (mediators of allergic inflammation). Over time, environmental stimuli such as infections activate Th1 responses and bring the Th1/Th2 relationship to an appropriate balance.
Evidence suggests that the prevalence of asthma is reduced in children who experience the following events:
- Certain infections (Mycobacterium tuberculosis, measles, or hepatitis A)
- Rural living
- Exposure to other children (eg, presence of older siblings and early enrollment in childcare
- Less frequent use of antibiotics, including in the first week of life[6]
- Early introduction of fish in the diet[6]
Furthermore, the absence of these lifestyle events is associated with the persistence of a Th2 cytokine pattern.
Under these conditions, the genetic background of the child, with a cytokine imbalance toward Th2, sets the stage to promote the production of immunoglobulin E (IgE) antibody to key environmental antigens (eg, dust mites, cockroaches, Alternaria, and possibly cats). Therefore, a gene-by-environment interaction occurs in which the susceptible host is exposed to environmental factors that are capable of generating IgE, and sensitization occurs.
A reciprocal interaction is apparent between the two subpopulations, in which Th1 cytokines can inhibit Th2 generation and vice versa. Allergic inflammation may be the result of an excessive expression of Th2 cytokines. Alternatively, recent studies have suggested the possibility that the loss of normal immune balance arises from a cytokine dysregulation in which Th1 activity in asthma is diminished.[7]
Results of two recently reported cross sectional studies of children growing up on farms in Central Europe who were exposed to greater variety of environmental microorganisms showed an inverse relationship between microbial exposure and the probability of asthma.[8]
Genetic factors
Some studies highlight the importance of genotypes in contributing to asthma susceptibility and allergic sensitization, as well as response to specific asthma treatments.[9, 10, 11, 12]
Through the use of cluster analysis, the Severe Asthma Research Program of the National Heart, Lung, and Blood Institute identified 5 phenotypes of asthma.[13] Cluster 1 patients have early-onset atopic asthma with normal lung function treated with two or fewer controller medications and minimal health care utilization. Cluster 2 patients have early-onset atopic asthma and preserved lung function but increased medication requirements (29% on three or more medications) and health care utilization.
Cluster 3 comprises mostly older obese women with late-onset nonatopic asthma, moderate reductions in pulmonary function, and frequent oral corticosteroid use to manage exacerbations. Cluster 4 and cluster 5 patients have severe airflow obstruction with bronchodilator responsiveness but differ in to their ability to attain normal lung function, age of asthma onset, atopic status, and use of oral corticosteroids.[13]
A recently reported meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations identified 5 susceptibility loci. Four were on previously reported loci on 17q21 and a new asthma susceptibility locus at PYHIN1, which is specific to the African American population.[14]
An Australian study identified 2 new loci with genome-wide significant association with asthma risk: rs4129267 in IL6R and rs7130588 on band 11q13.5. The IL6R association supports the hypothesis that cytokine dysregulation affects asthma risk, hence a specific antagonist to IL6R may help. The results for the 11q13.5 locus suggest its association with allergic sensitization and subsequent development of asthma.[15]
Other factors
Lemanske et al reported that wheezing illnesses caused by rhinovirus infection during infancy were the strongest predictor of wheezing in the third year of life.[16]
In a study of preschool children with asthma, Guilbert et al found that 2 years of inhaled corticosteroid therapy did not change the asthma symptoms or lung function during a third, treatment-free year. This suggests that no disease-modifying effect of inhaled corticosteroids is present after the treatment is discontinued.[17]
In a study of children in the Cincinnati area, Reponen et al found that a high Environmental Relative Moldiness Index (ERMI)[18] at age 1 year made asthma at age 7 years more likely. The ERMI did not predict specific mold allergies at age 7 years. Air conditioning made asthma less likely. An elevated ERMI at age 7 years had no correlation with current asthma. Seeing or smelling mold in a home inspection at age 1 year did not correlate with the ERMI or with the development of asthma. They also found that black race, having a parent with asthma, and house dust allergy was predictive of a greater likelihood of asthma.[19]
A recent study from Australia reported that obesity is a determinant of asthma control independent of inflammation, lung function, and airway hyperresponsiveness.[20] A similar association between increased risk of worse asthma control and obesity was reported in a recent retrospective study of 32,321 children aged 5-17 years.[21]
A significant inverse relationship between serum vitamin D levels and patient IgE levels, steroid requirements, and in vitro responsiveness to corticosteroids in children has been reported.[22]
Etiology
In most cases of asthma in children, multiple triggers or precipitants are recognized, and the patterns of reactivity may change with age. Treatment can also change the pattern. Certain viral infections, such as respiratory syncytial virus (RSV) bronchiolitis in infancy, predispose the child to asthma.
Respiratory infections
Most commonly, these are viral infections. In some patients, fungi (eg, allergic bronchopulmonary aspergillosis), bacteria (eg, Mycoplasma, pertussis), or parasites may be responsible. Most infants and young children who continue to have a persistent wheeze and asthma have high immunoglobulin E (IgE) production and eosinophilic immune responses (in the airways and in circulation) at the time of the first viral upper respiratory tract infection (URTI). They also have early IgE-mediated responses to local aeroallergens.
Allergens and irritants
In patients with asthma, 2 types of bronchoconstrictor responses to allergens are recognized: early and late. Early asthmatic responses occur via IgE-induced mediator release from mast cells within minutes of exposure and last for 20-30 minutes.
Late asthmatic responses occur 4-12 hours after antigen exposure and result in more severe symptoms that can last for hours and contribute to the duration and severity of the disease. Inflammatory cell infiltration and inflammatory mediators play a role in the late asthmatic response. Allergens can be foods, household inhalants (eg, animal allergens, molds, fungi, roach allergens, dust mites), or seasonal outdoor allergens (eg, mold spores, pollens, grass, trees).
Tobacco smoke, cold air, chemicals, perfumes, paint odors, hair sprays, air pollutants, and ozone can initiate BHR by inducing inflammation.
Other factors
Asthma attacks can be related to changes in atmospheric temperature, barometric pressure, and the quality of air (eg, humidity, allergen and irritant content). In some individuals, emotional upsets clearly aggravate asthma.
Exercise can trigger an early asthmatic response. Mechanisms underlying exercise-induced asthmatic response remain somewhat uncertain. Heat and water loss from the airways can increase the osmolarity of the fluid lining the airways and result in mediator release. Cooling of the airways results in congestion and dilatation of bronchial vessels. During the rewarming phase after exercise, the changes are magnified because the ambient air breathed during recovery is warm rather than cool.
The presence of acid in the distal esophagus, mediated via vagal or other neural reflexes, can significantly increase airway resistance and airway reactivity. Inflammatory conditions of the upper airways (eg, allergic rhinitis, sinusitis, or chronic and persistent infections) must be treated before asthmatic symptoms can be completely controlled.
Multiple factors have been proposed to explain nocturnal asthma. Circadian variation in lung function and inflammatory mediator release in the circulation and airways (including parenchyma) have been demonstrated. Other factors, such as allergen exposure and posture-related irritation of airways (eg, gastroesophageal reflux, sinusitis), can also play a role. In some cases, abnormalities in CNS control of the respiratory drive may be present, particularly in patients with a defective hypoxic drive and obstructive sleep apnea.
Epidemiology
Approximately 34.1 million people in the United States have been diagnosed with asthma in their lifetime. According to the most recent US Centers for Disease Control and Prevention (CDC) Asthma Surveillance Survey, the prevalence of current asthma during 2001-2003 prevalence is estimated at 6.7% in adults and 8.5% in children, and the burden of asthma increased more than 75% from 1980-1999.[23, 24]
Asthma accounts for more school absences and more hospitalizations than any other chronic illness. In most children's hospitals in the United States, it is the most common diagnosis at admission.
Worldwide, 130 million people have asthma. The prevalence is 8-10 times higher in developed countries (eg, United States, Great Britain, Australia, New Zealand) than in the developing countries. In developed countries, the prevalence is higher in low-income groups in urban areas and inner cities than in other groups.
Race-, sex-, and age-related demographics
The prevalence of asthma is higher in minority groups (eg, blacks, Hispanics) than in other groups; however, findings from one study suggest that much of the recent increase in the prevalence is attributed to asthma in white children. Approximately 5-8% of all black children have asthma at some time. The prevalence in Hispanic children is reported to be as high as 15%. In blacks, the death rate is consistently higher than in whites.
Before puberty, the prevalence of asthma is 3 times higher in boys than in girls. During adolescence, the prevalence is equal among males and females. Adult-onset asthma is more common in women than in men.
In most children, asthma develops before age 5 years, and, in more than half, asthma develops before age 3 years.
Among infants, 20% have wheezing with only upper respiratory tract infections (URTIs), and 60% no longer have wheezing by age 6 years. As Martinez et al have pointed out, however, many of these children are "transient wheezers" whose symptoms subside during the preschool or early school years.[25, 26] They tend to have no allergies, although their lung function is often abnormal. These findings have led to the idea that they have small lungs.
Children in whom wheezing begins early in conjunction with allergies are more likely to have wheezing when they are aged 6-11 years. Similarly, children in whom wheezing begins after age 6 years often have allergies, and the wheezing is more likely to continue when they are aged 11 years.[16]
Prognosis
Of infants who wheeze with URTIs, 60% are asymptomatic by age 6 years. However, children who have asthma (recurrent symptoms continuing at age 6 y) have airway reactivity later in childhood. Some findings suggest a poor prognosis if asthma develops in children younger than 3 years, unless it occurs solely in association with viral infections.
Individuals who have asthma during childhood have significantly lower forced expiratory volume in 1 second (FEV1), higher airway reactivity, and more persistent bronchospastic symptoms than those with infection-associated wheezing.
Children with mild asthma who are asymptomatic between attacks are likely to improve and be symptom-free later in life.
Children with asthma appear to have less severe symptoms as they enter adolescence, but half of these children continue to have asthma. Asthma has a tendency to remit during puberty, with a somewhat earlier remission in girls. However, compared with men, women have more BHR.
Mortality and morbidity associated with asthma
Globally, morbidity and mortality associated with asthma have increased over the last 2 decades. This increase is attributed to increasing urbanization. Despite advancements in the understanding of asthma and the development of new therapeutic strategies, the morbidity and mortality rates due to asthma definitely increased from 1980-1995.
In the United States, the mortality rate due to asthma has increased in all age, race, and sex strata. In the United States, the mortality rate due to asthma is more than 17 deaths per 1 million population (ie, 5000 deaths per year).
From 1975-1993, the number of deaths nearly doubled in people aged 5-14 years. In the northeastern and midwestern United States, the highest mortality rate has been among persons aged 5-34 years. According to the most recent report from the CDC and the National Center for Health Statistics, 187 children aged 0-17 years died from asthma, or 0.3 deaths per 100,000 children compared with 1.9 deaths per 100,000 adults aged 18 or older in the year 2002.[23]
Non-Hispanic blacks were the most likely to die from asthma and had an asthma death rate more than 200% higher than non-Hispanic whites and 160% higher than Hispanics.
Patient Education
Patient and parent education should include instructions on how to use medications and devices (eg, spacers, nebulizers, metered-dose inhalers [MDIs]). The patient's MDI technique should be assessed on every visit. Discuss the management plan, which includes instructions about the use of medications, precautions with drug and/or device usage, monitoring symptoms and their severity (peak flow meter reading), and identifying potential adverse effects and necessary actions.
Write and discuss in detail a rescue plan for an acute episode. This plan should include instructions for identifying signs of an acute attack, using rescue medications, monitoring, and contacting the asthma care team. Parents should understand that asthma is a chronic disorder with acute exacerbations; hence, continuity of management with active participation by the patient and/or parents and interaction with asthma care medical personnel is important. Emphasize the importance of adherence to treatment.
Incorporate the concept of expecting full control of symptoms, including nocturnal and exercise-induced symptoms, in the management plans and goals (for all but the most severely affected patients). Avoid unnecessary restrictions in the lifestyle of the child or family. Expect the child to participate in recreational activities and sports and to attend school as usual.
A systematic review by Coffman and colleagues suggested a benefit school-based asthma education. Their review included 25 studies in children aged 4-17 years.[27] In most of those studies, compared with usual care, school-based asthma education improved knowledge of asthma (7 of 10 studies), self-efficacy (6 of 8 studies), and self-management behaviors (7 of 8 studies). Fewer studies reported favorable effects on quality of life (4 of 8 studies), days of symptoms (5 of 11 studies), nights with symptoms (2 of 4 studies), and school absences (5 of 17 studies).[27]
For patient education information, see the Asthma Center, as well as Asthma, Asthma FAQs, Understanding Asthma Medications, Asthma in Children, and Asthma in School Children: Educational Slides.
National Heart, Lung, and Blood Institute. Global Initiative for Asthma. National Institute for Health Publication. 1995;95-3659.
Global strategy for asthma management and prevention. Global initiative for asthma (GINA) 2006. Available at http://ginasthma.org.
Akinbami LJ, Moorman JE, Garbe PL, Sondik EJ. Status of childhood asthma in the United States, 1980-2007. Pediatrics. Mar 2009;123 Suppl 3:S131-45. [Medline].
National Health Interview Survey, National Center for Health Statistics. CDC. Available at http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ashtma03-05/asthma03-05.htm.
Anderson WJ, Watson L. Asthma and the hygiene hypothesis. N Engl J Med. May 24 2001;344(21):1643-4. [Medline].
Goksör E, Alm B, Thengilsdottir H, Pettersson R, Aberg N, Wennergren G. Preschool wheeze - impact of early fish introduction and neonatal antibiotics. Acta Paediatr. Dec 2011;100(12):1561-6. [Medline].
Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. May 2000;161(5):1720-45. [Medline].
Ege MJ, Mayer M, Normand AC, Genuneit J,et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med. Feb 24 2011;364(8):701-9. [Medline].
Zucker, M. Asthma phenotype, genotype may guide future therapies. http://www.pulmonaryreviews.com [serial online]. June 2003;8:Available at http://www.pulmonaryreviews.com/jun03/pr_jun03_phenotype.html.
Drazen JM, Yandava CN, Dubé L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. Jun 1999;22(2):168-70. [Medline].
Thompson EE, Pan L, Ostrovnaya I, Weiss LA, Gern JE, Lemanske RF Jr, et al. Integrin beta 3 genotype influences asthma and allergy phenotypes in the first 6 years of life. J Allergy Clin Immunol. Jun 2007;119(6):1423-9. [Medline].
Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. Mar 1 2006;173(5):519-26. [Medline]. [Full Text].
Moore WC, Meyers DA, Wenzel SE, Teague WG, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. Feb 15 2010;181(4):315-23. [Medline]. [Full Text].
Torgerson DG, Ampleford EJ, Chiu GY, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet. Jul 31 2011;43(9):887-92. [Medline].
Ferreira MA, Matheson MC, Duffy DL, et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet. Sep 10 2011;378(9795):1006-14. [Medline].
Lemanske RF Jr, Jackson DJ, Gangnon RE, Evans MD, Li Z, Shult PA, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. J Allergy Clin Immunol. Sep 2005;116(3):571-7. [Medline].
[Best Evidence] Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. May 11 2006;354(19):1985-97. [Medline].
Vesper S, McKinstry C, Haugland R, et al. Development of an Environmental Relative Moldiness index for US homes. J Occup Environ Med. Aug 2007;49(8):829-33. [Medline].
Reponen T, Vesper S, Levin L, et al. High environmental relative moldiness index during infancy as a predictor of asthma at 7 years of age. Ann Allergy Asthma Immunol. Aug 2011;107(2):120-6. [Medline].
Farah CS, Kermode JA, Downie SR, et al. Obesity is a determinant of asthma control independent of inflammation and lung mechanics. Chest. Sep 2011;140(3):659-66. [Medline].
Quinto KB, Zuraw BL, Poon KY, Chen W, Schatz M, Christiansen SC. The association of obesity and asthma severity and control in children. J Allergy Clin Immunol. Nov 2011;128(5):964-9. [Medline].
Goleva E, Searing DA, Jackson LP, Richers BN, Leung DY. Steroid requirements and immune associations with vitamin D are stronger in children than adults with asthma. J Allergy Clin Immunol. Feb 11 2012;[Medline].
Asthma prevalence and control characteristics by race/ethnicity--United States, 2002. MMWR Morb Mortal Wkly Rep. Feb 27 2004;53(7):145-8. [Medline].
Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, et al. National surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ. Oct 19 2007;56(8):1-54. [Medline].
Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. Jan 19 1995;332(3):133-8. [Medline].
Castro-Rodríguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. Oct 2000;162(4 Pt 1):1403-6. [Medline].
[Best Evidence] Coffman JM, Cabana MD, Yelin EH. Do school-based asthma education programs improve self-management and health outcomes?. Pediatrics. Aug 2009;124(2):729-42. [Medline]. [Full Text].
[Guideline] Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. Nov 2007;120(5 Suppl):S94-138. [Medline].
Wu AC, Tantisira K, Li L, Schuemann B, Weiss ST, Fuhlbrigge AL. Predictors of Symptoms are Different from Predictors of Severe Exacerbations from Asthma in Children. Chest. Feb 3 2011;[Medline].
Stern G, de Jongste J, van der Valk R, Baraldi E, Carraro S, Thamrin C, et al. Fluctuation phenotyping based on daily fraction of exhaled nitric oxide values in asthmatic children. J Allergy Clin Immunol. Aug 2011;128(2):293-300. [Medline].
Holbrook JT, Wise RA, Gold BD, et al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA. Jan 25 2012;307(4):373-81. [Medline].
[Best Evidence] Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. Jan 2006;129(1):15-26. [Medline].
[Best Evidence] Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med. Apr 2010;123(4):322-8.e2. [Medline].
US Food and Drug Administration. FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABA). Human Department of Health and Human services. Feb 18, 2010;1-4. [Full Text].
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. March 30, 2010;362:975-85.
[Best Evidence] Rachelefsky G. Inhaled corticosteroids and asthma control in children: assessing impairment and risk. Pediatrics. Jan 2009;123(1):353-66. [Medline].
Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. Feb 19 2011;377(9766):650-7. [Medline].
Quon BS, Fitzgerald JM, Lemière C, Shahidi N, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. Dec 8 2010;CD007524. [Medline].
Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. Oct 12 2000;343(15):1064-9. [Medline].
Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med. Oct 12 2000;343(15):1054-63. [Medline].
Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest. Jan 2011;139(1):28-35. [Medline].
Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. Mar 17 2011;364(11):1005-15. [Medline].
[Best Evidence] Cates CJ, Bestall J, Adams N. Holding chambers versus nebulisers for inhaled steroids in chronic asthma. Cochrane Database Syst Rev. Jan 25 2006;CD001491. [Medline].
[Best Evidence] Vuillermin PJ, Robertson CF, Carlin JB, Brennan SL, Biscan MI, South M. Parent initiated prednisolone for acute asthma in children of school age: randomised controlled crossover trial. BMJ. Mar 1 2010;340:c843. [Medline]. [Full Text].
Halterman JS, Szilagyi PG, Fisher SG, Fagnano M, Tremblay P, Conn KM, et al. Randomized controlled trial to improve care for urban children with asthma: results of the school-based asthma therapy trial. Arch Pediatr Adolesc Med. Mar 2011;165(3):262-8. [Medline].
Postma DS, O'Byrne PM, Pedersen S. Comparison of the effect of low-dose ciclesonide and fixed-dose fluticasone propionate and salmeterol combination on long-term asthma control. Chest. Feb 2011;139(2):311-8. [Medline].
| Intermittent Asthma | Persistent Asthma: Daily Medication | |||||
| Age | Step 1 | Step 2 | Step 3 | Step 4 | Step 5 | Step 6 |
| < 5 y | Rapid-acting beta2-agonist prn | Low-dose inhaled corticosteroid (ICS) | Medium-dose ICS | Medium-dose ICS plus either long-acting beta2-agonist (LABA) or montelukast | High-dose ICS plus either LABA or montelukast | High-dose ICS plus either LABA or montelukast; Oral systemic corticosteroid |
| Alternate regimen: cromolyn or montelukast | ||||||
| 5-11 y | Rapid-acting beta2-agonist prn | Low-dose ICS | Either low-dose ICS plus either LABA, LTRA, or theophylline OR Medium-dose | Medium-dose ICS plus LABA | High-dose ICS plus LABA | High-dose ICS plus LABA plus oral systemic corticosteroid |
| Alternate regimen: cromolyn, leukotriene receptor antagonist (LTRA), or theophylline | Alternate regimen: medium-dose ICS plus either LTRA or theophylline | Alternate regimen: high-dose ICS plus either LABA or theophylline | Alternate regimen: high-dose ICS plus LRTA or theophylline plus systemic corticosteroid | |||
| 12 y or older | Rapid-acting beta2-agonist as needed | Low-dose ICS | Low-dose ICS plus LABA OR Medium-dose ICS | Medium-dose ICS plus LABA | High-dose ICS plus LABA (and consider omalizumab for patients with allergies) | High-dose ICS plus either LABA plus oral corticosteroid (and consider omalizumab for patients with allergies) |
| Alternate regimen: cromolyn, LTRA, or theophylline | Alternate regimen: low-dose ICS plus either LTRA, theophylline, or zileuton | Alternate regimen: medium-dose ICS plus either LTRA, theophylline, or zileuton | ||||

